Sanofi and Regeneron Pharmaceuticals have announced the data from two Phase 2 primary hypercholesterolemia trials with SAR236553/REGN727, designed to lower low-density lipoprotein (LDL) cholesterol in patients.

SAR236553/REGN727 is a high-affinity, subcutaneously administered, fully-human monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), a determinant of circulating LDL-cholesterol levels in the blood.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Study 11565 was a randomised double-blind multi-dose placebo-controlled trial that administered 183 patients with one of five different dose regimens of SAR236553/REGN727 – either 50mg, 100mg, or 150mg Q2W, or 200mg or 300mg Q4W alternating with placebo at two weeks – plus continued atorvastatin or placebo.

In the randomised double-blind multi-dose placebo-controlled Study 11566, 92 patients were randomised to either titration from atorvastatin 10mg to atorvastatin 80mg plus SAR236553/REGN727 150mg Q2W, titration from atorvastatin 10mg to atorvastatin 80mg plus placebo, or continued atorvastatin 10mg plus SAR236553/REGN727 150mg Q2W.

The primary endpoint of Study 11565 was the change in LDL-cholesterol from baseline over the 12-week study period, while in Study 11566 it was the change in LDL-cholesterol from baseline over the eight-week study period.

Both trials showed that treatment with SAR236553/REGN727 over eight to 12 weeks considerably reduced mean low-density lipoprotein-cholesterol by 40% to 72% in patients with elevated LDL-C on a stable dose of statins.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

National Clinical Research president and CEO and principal investigator of the study James McKenney said the trial results suggest that SAR236553/REGN727 may enable patients for whom statins are insufficient to further reduce LDL-C.

Sanofi global research and development president Elias Zerhouni said genetic data has shown that patients with natural loss-of-function mutations in PCSK9 have lower LDL-C and a lower risk of coronary heart disease.

"Based on this finding and the results of our Phase 2 trials, Sanofi and Regeneron plan to initiate the SAR236553/REGN727 Phase 3 program in the second quarter," Zerhouni added.